About this trial
In this study the investigators aim to identify and include consecutively patients with primary aldosteronism (PA) diagnosed in the Western and Mid-parts of Norway, to describe the characteristics of these patients, to explore the cardiac effects of PA before and after specific treatment, and to identify long-term outcomes after treatment. One subgroup of the PA patients perform echocardiography to assess left ventricular systolic myocardial function before and after treatment. One subgroup of PA patients perform cardiac MRI to assess myocardial mass, myocardial fibrosis and myocardial function in rest and during stress, before and after treatment. For the cardiac MRI substudy, the PA patients are compared with a group of healthy controls, also included in the study.
From 2022 onwards, PA patients diagnosed or subtyped with adrenal vein sampling at Oslo University Hospital will additionally be included in the study, thereby providing a national registration of PA patients.
Eligibility criteria
Qualifiers
Verified diagnosis or strong suspicion of primary aldosteronism
Age 18-85
Disqualifiers
Active cancer disease at time of inclusion
Asthma/chronic obstructive pulmonary disease ,
Use of dipyridamole
Claustrophobia
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Haukeland University Hospital
Lead sponsor
Oslo University Hospital
Collaborator
Helse Stavanger HF
Collaborator
Helse Fonna
Collaborator
University Hospital of North Norway
Collaborator
St. Olavs Hospital
Collaborator
Alesund Hospital
Collaborator